Immunome (NASDAQ:IMNM) Shares Gap Up to $15.48

Shares of Immunome, Inc. (NASDAQ:IMNM) gapped up prior to trading on Monday . The stock had previously closed at $15.48, but opened at $16.06. Immunome shares last traded at $15.37, with a volume of 176,914 shares trading hands.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on IMNM shares. SVB Leerink started coverage on shares of Immunome in a research note on Monday, January 29th. They set an “outperform” rating and a $30.00 price objective on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. Guggenheim started coverage on shares of Immunome in a research report on Monday, April 15th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Wedbush boosted their price target on shares of Immunome from $27.00 to $33.00 and gave the stock an “outperform” rating in a research report on Monday, April 1st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Immunome currently has a consensus rating of “Buy” and a consensus price target of $32.67.

Immunome Trading Down 2.5 %

The company’s fifty day simple moving average is $22.88 and its 200-day simple moving average is $14.97. The stock has a market cap of $900.72 million, a P/E ratio of -2.93 and a beta of 1.66.

Immunome (NASDAQ:IMNM) last issued its earnings results on Thursday, March 28th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.26). The firm had revenue of $3.83 million during the quarter, compared to analyst estimates of $3.40 million. Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. As a group, analysts expect that Immunome, Inc. will post -1.91 earnings per share for the current fiscal year.

Institutional Trading of Immunome

A number of large investors have recently bought and sold shares of IMNM. TD Asset Management Inc acquired a new stake in shares of Immunome in the 3rd quarter valued at approximately $1,063,000. Dorsey Wright & Associates acquired a new stake in Immunome during the 3rd quarter valued at $26,000. Acadian Asset Management LLC bought a new position in Immunome during the 3rd quarter worth $414,000. Cerity Partners LLC bought a new position in Immunome during the 4th quarter worth $656,000. Finally, Emfo LLC bought a new position in Immunome during the 4th quarter worth $633,000. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.